BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LYNC-101 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of LYNC-101\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07505030-61@assetmemo.bio
DTSTAMP:20261121T004549Z
DTSTART;VALUE=DATE:20270319
DTEND;VALUE=DATE:20270320
SUMMARY:LYNC-101: Phase 1 readout est. (NCT07505030)
DESCRIPTION:LYNC-101\, phase 1\, Ulcerative Colitis.\nStudy: To Evaluate th
 e Safety\, Tolerability\, Pharmacokinetics\, Pharmacodynamics\, and Immuno
 genicity of LYNC-101 for Injection in Healthy Adult Participants\nEstimate
 d primary completion: 19 March 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/lync-101#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07505030
URL:https://assetmemo.bio/drug/lync-101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
